Chairman Won “Pharmaceutical Bio Open Innovation will do its best for global success”
Won Hee-mok, chairman of the Korea Pharmaceutical Bio Association, will take the lead for two more years to innovate the domestic pharmaceutical bio industry and become a global leader until February 2023.
The association’s presidency (Chairman Gwan-soon Lee) held the 1st meeting in 2021 on the afternoon of January 19 and unanimously decided to extend the term of office for the current President Hee-mok Won. According to the Articles of Incorporation (Article 13), a president who has a two-year term of office may be reappointed once, and only the president who has been reappointed can be extended one term by a special resolution of the chairman and directors if necessary. Chairman Won took office as the 21st president in February 2017, and reappointed as president for two years in February 2019.
On this day, the chairman and director said, “In the corona 19 pandemic, considering the national expectations of the pharmaceutical bio industry and the challenges of the times, Chairman Won, who has been leading the association, is the best person to derive tangible results from the establishment of the foundation for global success and pharmaceutical sovereignty in our industry. He said, “Unanimously, I decided to ask President Won for two more years of hard work.”
Accordingly, Chairman Won said, “I would like to express my special gratitude to the member companies and executives and employees of the association who are doing their best to develop the industry and overcome Corona 19. In particular, he felt a heavy responsibility for the trust and expectations of the chairman and the chairman who gave great strength through proactive directions and cooperation. “We will focus on solidifying the various public-private partnerships and industrial innovation projects we have been pursuing so far to systemize more solidly, and to maximize synergy in a virtuous cycle and organically.” Added.
Immediately after taking office in 2017, Chairman Won named’the pharmaceutical industry is a logistics base for health and security and a food for the future’, and secured growth engines along with topics such as’The only way to live by R&D investment’ and’Ethical management is the trend’. They demanded bold industrial support from the government. Accordingly, the Moon Jae-in administration specified support for the pharmaceutical industry as one of the top 100 national tasks in 2018, and selected the bio industry as one of the three major industries along with future vehicles and system semiconductors in 2020. Pulled out.
In addition, ISO 37001 (Anti-Corruption Management System) in line with international standards was introduced to promote the participation of member companies to establish ethical management and enhance market transparency. In addition, in order to create a new drug development environment using artificial intelligence (AI), the Korea Health Industry Promotion Agency and the AI New Drug Development Support Center were established in 2019 to preemptively respond to the new drug development paradigm based on convergence.
In particular, it focused on revitalizing open innovation and securing a base for global expansion. Exchange and cooperation, such as regularly holding’Bio Open Plaza’, which seeks collaboration among companies, academia, research institutes, medical institutions, etc. to function as a hub for various open innovations such as between pharmaceutical companies and between pharmaceutical companies and bioventures Made a chapter.
In 2020, the Korea Innovative Medicines Consortium (KIMCo) was launched for the first time in collaboration with the association and member companies to support joint responses to infectious diseases and the development of innovative new drugs.
In addition, K-NIBRT contributed to attracting Incheon Songdo in 2020 through field visits and continuous exchanges with Ireland’s National Bioengineering Human Resources Development Center (NIBRT), which is said to be the world’s best biopharmaceutical manpower training institution, and the Cambridge Innovation Center (CIC). ), and joining the Massachusetts Institute of Technology (MIT) Industry-Academic Partnership Program (ILP) consortium, etc., led to tangible results in advancing into global advanced markets and activating technology exchange.
Meanwhile, Chairman Won, a graduate of Seoul National University Pharmacy University, has served as the president of the Korean Pharmaceutical Association (the 33rd and 34th), the 18th National Assembly member (the National Assembly Health and Welfare Committee), and the Director of the Social Security Intelligence Agency.